Market Research Life Sciences Market Research Healthcare Market Research Facilities Market Research Laboratories Market Research

Next-Generation Sequencing Market and Kalorama Survey of NGS Laboratories

Best Price Guarantee Length Publisher Published Date SKU
from $6,000 86 Pages Kalorama Information August, 2019 KLI16038423
Best Price Guarantee
Price from $6,000
Length 86 Pages
Publisher Kalorama Information
Published Date August, 2019
SKU KLI16038423

Next-Generation Sequencing Market and Kalorama Survey of NGS Laboratories

Next-generation sequencing (NGS) technologies encompass the modern, post-Sanger sequencing techniques that revolutionized and expanded the fields of molecular biology and genomics in recent years. NGS has been a disruptive technology that had a substantial impact on the characterization of the genome of various species and has found numerous applications in a large variety of fields, including clinical diagnostics, drug discovery and development, agriculture, and forensics. Next-Generation Sequencing Market and Kalorama Survey of NGS Laboratories provides an in-depth look at the sequencing market, including data for 2018-2023 for the following markets:

  • NGS Sequencing Market, 2018-2023
  • Estimated Sequencing System Market Revenues, 2018-2023
  • Estimated Sequencing System Consumable Market Revenues, 2018-2023
  • Estimated Sequencing System Market Revenues, 2018-2023
  • Estimated Shares by Product Type, 2018 (%)
  • Forecast Shares by Product Type, 2023 (%)
  • Regional Breakout and Market Share by Vendor
This report includes a Survey of Labs Using Next-Generation Sequencing. The survey was conducted by an experienced NGS market analyst who interviewed lab managers and directors to obtain a real-world view point on the next-generation sequencing market today.
  • Please describe the lab’s industry and function?
  • How many sequencers does the laboratory have, and which models?
  • For your most recent sequencers, please describe: the model, what applications are run typically (by percentage), how often or how many samples (runs, samples, slides, flow cells, plates, multiplexed or not).
  • Which applications are expected to increase most?
  • Does the lab outsource any sequencing? For what reason(s)?
  • How does the lab/ organization address regulated patient samples?
  • Does the lab have accreditation for regulated patient samples?
  • Which sequencers are used for regulated and non-regulated patient samples?
  • In what disease areas does the lab sequence regulated/ non-regulated patient/ human samples? What disease areas are expected to grow the most from 2017-2018?
  • What percentage of samples sequenced are patient samples subject to regulation, patient/ human samples not subject to regulation, and non-patient/ non-human samples not subject to regulation? How is this expected to change from 2017-2018
  • How much is the volume of NGS and capillary sequencing expected to change overall from 2017 to 2018?
  • What sequencer features, or steps in the sequencing process would you most like to be changed/ improved?
  • What is the main bottleneck in your sequencing process (ie at what step do things back up)?
  • How challenging are data analysis and data management?
  • Which systems would the lab most likely consider for future purchases?
  • What is the likely time-frame for future sequencer purchases?
  • Which systems are likely to be used in the future for regulated patient samples (and are not being used currently for that)?
  • What barriers or other issues would hinder the growth of sequencing, particularly NGS, in clinical areas?
Company profiles – next-generation sequencing companies:
  • 10X Genomics
  • BGI Genomics (formerly Beijing Genome Institute)
  • Illumina
  • Oxford Nanopore
  • Promega Corporation
  • Qiagen N.V.
  • Roche Diagnostics
  • Swift Biosciences
  • Thermo Fisher Scientific Inc.


  • Market Analysis and Report Summary
    • Overall Sequencing Market Revenues
      • Table NGS Sequencing Market, 2018-2023
      • Table Estimated Sequencing System Market Revenues, 2018-2023
      • Table Estimated Sequencing System Consumable Market Revenues, 2018-2023
      • Table Estimated Sequencing System Market Revenues, 2018-2023
      • Table Estimated Shares by Product Type, 2018 (%)
      • Table Forecast Shares by Product Type, 2023 (%)
      • Regional Breakout
        • Table Regional Breakout
      • Market Share
        • Table Market Share by Vendor
    • Scope
    • Methodology
    • Outline
    • Demographics
      • Regional Distribution of Respondents' Labs
        • Table Regional Distribution of Respondent Labs
        • Table Regional Distribution of Respondent Labs (%)
      • Industrial Distribution of Respondents' Labs
        • Table Primary Industry/ Segment Labs Belong To
        • Table Primary Industry/ Segment Labs Belong To (%)
        • Table Industry/ Segment(s) Labs Belong To, by Region
        • Table Industry/ Segment(s) Labs Belong To, by Region (%)
      • Laboratory Function of Respondents' Labs
        • Table Major Function(s) of Respondent Labs
        • Table Major Function(s) of Respondent Labs (%)
        • Table Major Function(s) of Labs, by Region
        • Table Major Function(s) of Labs, by Region (%)
      • Distribution by Number of Sequencers
        • Table Distribution of Total Sequencers in Labs
        • Table Number of Next-Generation Sequencers in Labs
        • Table Number of ABI Capillary Sequencers in Labs
      • Brand(s)/ Types(s) of Sequencers Owned, Overall
        • Table Brand(s)/ Type(s) of Sequencers Owned by Labs
        • Table Number of a Given Brand / Type in Labs Owning Type, 2019
        • Table Avg. Number of a Given Sequencer in Labs Owning Type, 2019
        • Table Number of a Given Brand / Type in Labs Owning Type, 2017
        • Table Avg. Number of a Given Sequencer in Labs Owning Type, 2017
      • Library Preparation and Other Automation
        • Table Library Preparation and Automation Systems
      • Position/ Role of Respondents
        • Table Position/ Role of Respondent
        • Table Position/ Role of Respondent (%)
  • System Installations
    • Overall Installed Base
      • Distribution of Sequencer Models
        • Table Sequencer Models in Respondents' Labs
        • Table Sequencer Models in Respondents' Labs (%)
        • Table Installed Base of Labs, by System(s) Owned (# of Systems)
        • Table Installed Base of Labs, by System(s) Owned (% of Systems)
      • Distribution of Number of Sequencers
        • Table Distribution of NGS vs. Capillary Systems (# of Labs)
        • Table # of NGS Systems by # of Capillary Systems (% of Labs)
        • Table # of Capillary Systems by # of NGS Systems (% of Labs)
    • Installed Base by Region
      • Overall Brand/ Type
        • Table Number of Systems Installed in Labs, by Region
        • Table Sequencer Models in Respondents' Labs, by Region (# of Systems)
        • Table Sequencer Models in Respondents' Labs, by Region (% of Systems)
      • Next-Generation Systems
        • Table NGS Models in Respondents' Labs, by Region (# of Systems)
        • Table NGS Models in Respondents' Labs, by Region (% of Systems)
      • Capillary Systems
        • Table Capillary Models in Respondents' Labs, by Region (# of Systems)
        • Table Capillary Models in Respondents' Labs, by Region (% of Systems)
    • Installed Base by Industry Segment
      • Overall Brand/ Type
        • Table Number of Systems Installed, by Industry/ Segment(s)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (# of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2017 (% of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (# of Systems)
        • Table Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (% of Systems)
      • Next-Generation Systems
        • Table Number of NGS Systems Installed, by Industry/ Segment
        • Table Next-Generation Models in Respondents' Labs, by Industry/ Segment (# of Systems)
        • Table Next-Generation Models in Respondents' Labs, by Industry/ Segment (% of Systems)
      • Capillary Systems
        • Table Number of Capillary Systems Installed in Labs Owning, by Industry/ Segment
    • Installed Base by Laboratory Function
      • Overall Brand/ Type
        • Table Number of Systems Installed by Laboratory Function
        • Table Brand / Type of Sequencer System Installed, by Lab Function (# of Systems)
        • Table Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
      • Next-Generation Systems
        • Table Number of NGS Installed in Labs Owning, by Lab Function
        • Table NGS Models in Respondents' Labs, by Lab Function (# of Systems)
        • Table NGS Models in Respondents' Labs, by Lab Function (% of Systems)
        • Table NGS Models in Respondents' Labs, by Lab Function (% of Systems)
      • Capillary / Gel Systems
        • Table Number of Capillary Systems Installed in Labs Owning, by Lab Function
  • Sequencer Applications, Clinical Applications, and Usage Trends
    • Sequencer Applications and Usage
      • Applications Run, Overall and by Brand/ Type
        • Table NGS Application Volume by Model (% of Sequencing)
      • Likely Increases in Applications and Volume
        • Table Applications Expected to Increase the Most, 2019
        • Table Applications Expected to Increase the Most Overall (%)
        • Table Applications Expected to Increase, by NGS Brand Owned (# of Labs)
        • Table Applications Expected to Increase, by NGS Brand Owned (% of Labs)
        • Table Expected Growth in Sequencing Volume (# of Labs)
        • Table Expected Growth in Sequencing Volume (% of Labs)
      • Capacity Usage of Systems
        • Table Avg. Percentage of Systems' Capacity Used, by Brand
        • Table Percentage of Systems' Capacity Used, by Brand
      • Outsourcing
        • Table Percentage of Sequencing Volume Outsourced
        • Table Percentage of Sequencing Volume Outsourced, by Region
        • Table Reasons for Outsourcing
        • Table Reasons for Outsourcing (%)
    • Clinical Applications
      • Sequencing of CLIA Regulated Patient Samples
        • Table How Labs Address Sequencing of Regulated Patient Samples (# of Labs)
        • Table How Labs Address Sequencing of Regulated Patient Samples (% of Labs)
      • Certification for Regulated Samples
        • Table Labs' Certification for Regulated Patient Samples
        • Table Labs' Certification for Regulated Patient Samples (%)
        • Table Distribution of Samples, Est. 2018 (# of Labs)
        • Table Distribution of Samples, Est. 2017 (% of Labs)
        • Table Distribution of Samples, Est. 2018 (% of Labs)
        • Table Distribution of Samples, Expected 2019 (# of Labs)
        • Table Distribution of Samples, Expected 2019 (% of Labs)
        • Table Proportion of Regulated vs. Non-Regulated Samples (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples, Est. 2018 (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples, Expected 2019 (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples, est. 2018 (% of Sequencing)
        • Table Proportion of Regulated vs. Non-Regulated Samples, Expected 2014 (% of Sequencing)
      • Sequencers Used or Planned for Patient/ Human Samples
        • Table Sequencers Used for Regulated Patient Samples
        • Table Sequencers Used for Regulated Patient Samples (% of Systems)
      • Disease/ Therapeutic Areas Where Sequencing Applied
        • Table Disease Areas Where Sequencing Applied, NGS (Percentage and Number of Systems)
        • Table Disease Areas Where Sequencing Applied (%)
        • Table Regulated Sequencing Expected to Grow Fastest
        • Table Regulated Sequencing Expected to Grow Fastest (% of Labs)
        • Table Non-Regulated Patient/ Human Sequencing Expected to Grow Fastest
      • Challenges for Growth of Clinical Sequencing
        • Table Challenges for Growth of Clinical Sequencing
  • Preferences and Evaluations
    • Key Criteria for Choosing Sequencers
      • Overall
        • Table Most Important Criteria for Sequencer Purchase
        • Table Most Important Criteria for Sequencer Purchase (%)
      • By Next-Generation Systems vs Capillary Systems
        • Table Most Important Criteria for Purchases, by Brand Owned
    • Changes or Improvements
      • Table Feature Most Wanted to Change or Improve
      • Table Feature Most Wanted to Change or Improve (%)
    • Bottlenecks in Process
      • Table Bottlenecks in the NGS Process
      • Table Bottlenecks in the NGS Process (%)
  • Future Purchase Plans
    • Time-Frame of Purchase Plans
      • Overall
        • Table Time Frame for Future Purchase
        • Table Time Frame for Future Purchase (%)
      • By Brand/ Type Owned
        • Table Time Frame for Future Purchase, by Brand Owned (# of Labs)
        • Table Time Frame for Future Purchase, by Brand Owned (% of Labs)
      • By Laboratory Function
        • Table Time Frame for Future Purchase, by Lab Function (# of Labs)
        • Table Time Frame for Future Purchase, by Lab Function (% of Labs)
      • By Region
        • Table Time Frame for Future Purchase, by Region (# of Labs)
        • Table Time Frame for Future Purchase, by Region (% of Labs)
    • Systems Likely to Consider for Purchase
      • Overall
        • Table Sequencer Models Likely to Consider, 2019-2020
        • Table Sequencer Models Likely to Consider (% of Labs)
      • By Brand/ Type Owned
        • Table Sequencer Models Likely to Consider, by Brand/ Type Owned (# of Labs)
        • Table Sequencer Models Likely to Consider, by Brand/ Type Owned (% of Labs)
      • By Industry/ Segment
        • Table Sequencer Models Likely to Consider, by Industry/ Segment Owned (# of Labs)
        • Table Sequencer Models Likely to Consider, by Industry/ Segment Owned (% of Labs)
      • By Laboratory Function
        • Table Sequencer Models Likely to Consider, by Lab Function (# of Labs)
        • Table Sequencer Models Likely to Consider, by Lab Function (% of Labs)
      • By Region
        • Table Sequencer Models Likely to Consider, by Region (# of Labs)
        • Table Sequencer Models Likely to Consider, by Region (% of Labs)
  • Company Profiles
    • 10X Genomics
    • BGI Genomics (formerly Beijing Genome Institute)
    • Illumina
      • Key Comment
      • Recent Revenue History
      • Company Reported Highlights in 2018
    • Oxford Nanopore
    • Promega Corporation
    • QIAGEN N.V.
      • Key Comment
      • Recent Revenue History
      • Tuberculosis
      • Molecular Expansion
      • Precision Medicine / Companion Diagnostics
      • Liquid Biopsy
    • Roche Diagnostics
      • Key Comment
      • Revenues
    • Swift Biosciences
    • Thermo Fisher Scientific Inc.
      • Key Comment
      • Recent Revenue History
      • Next Generation Sequencing
  • Appendix: Library Preparation
    • Table Library Preparation Related Systems (% of Systems, Count)
    • Table Library Preparation Related Systems (% of Systems)
    • Table Library Preparation Related Systems (% of Labs Responding, Count)
    • Table Library Preparation Related Systems (% of Labs Responding)

$6,000
$9,000
$12,000

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings